| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 72603-0402-01 | 72603-0402 | Pegflilgrastim-fpgk | STIMUFEND | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | Subcutaneous | Dec 29, 2025 | In Use | |
| 83831-0149-50 | 83831-0149 | Leucovorin calcium | VYKOURA | 500.0 mg/50mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Mar 16, 2026 | In Use | |
| 00143-9771-06 | 00143-9771 | Ondansetron Hydrochloride and Dextrose | Ondansetron Hydrochloride and Dextrose | 32.0 mg/50mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Aug 4, 2009 | In Use | |
| 76310-0002-01 | 76310-0002 | Dexrazoxane | Cardioxane | 500.0 mg/1 | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Jul 28, 2017 | In Use | |
| 80175-0017-05 | 80175-0017 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 11, 2018 | In Use | |
| 63629-4093-07 | 63629-4093 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 27, 2010 | In Use | |
| 00006-3884-32 | 00006-3884 | Fosaprepitant Dimeglumine | Emend | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Jan 25, 2008 | Jul 31, 2012 | No Longer Used | ||
| 83831-0148-35 | 83831-0148 | Leucovorin calcium | VYKOURA | 350.0 mg/35mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Mar 16, 2026 | In Use | |
| 63187-0526-12 | 63187-0526 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 20, 2023 | In Use | |
| 51079-0525-01 | 51079-0525 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 9, 2007 | Apr 30, 2019 | No Longer Used |
| 00603-3633-21 | 00603-3633 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec 22, 2006 | Feb 28, 2018 | No Longer Used |
| 71288-0155-01 | 71288-0155 | Plerixafor | Plerixafor | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Jul 24, 2023 | In Use | |
| 00006-4045-01 | 00006-4045 | Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant | GARDASIL | 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Jun 8, 2006 | In Use | |
| 00172-7311-46 | 00172-7311 | Cyclosporine Modified | Cyclosporine Modified | 50.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Apr 28, 2005 | Feb 28, 2017 | No Longer Used |
| 55513-0924-91 | 55513-0924 | Filgrastim | Neupogen | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Oct 2, 2000 | In Use | |
| 51407-0704-03 | 51407-0704 | APREPITANT | APREPITANT | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Jun 11, 2025 | In Use | |
| 60760-0313-10 | 60760-0313 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 2, 2020 | In Use | |
| 71930-0018-52 | 71930-0018 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 6, 2020 | In Use | |
| 70786-0090-03 | 70786-0090 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Aug 3, 2016 | Aug 5, 2016 | No Longer Used |
| 55150-0175-01 | 55150-0175 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jul 6, 2016 | In Use | |
| 68001-0669-15 | 68001-0669 | Aprepitant | Aprepitant | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Feb 3, 2026 | In Use | |
| 00179-0175-88 | 00179-0175 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 26, 2015 | Jul 31, 2020 | No Longer Used |
| 25021-0782-20 | 25021-0782 | ondansetron hydrochloride | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Aug 30, 2012 | Nov 30, 2021 | No Longer Used |
| 00088-1208-06 | 00088-1208 | Dolasetron mesylate | Anzemet | 12.5 mg/.625mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sep 11, 1997 | Aug 31, 2016 | No Longer Used |
| 55513-0048-01 | 55513-0048 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Feb 10, 2004 | Feb 28, 2009 | No Longer Used |
Found 12393 results — Export these results
Home